Nuvalent Inc NUVL

NAS: NUVL | ISIN: US6707031075   17/05/2024
70,88 USD (-2,42%)
(-2,42%)   17/05/2024

16 mei 2024 · Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-655 · Persbericht

9 mei 2024 · Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2024 Financial Results · Persbericht

8 april 2024 · Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024 · Persbericht

5 maart 2024 · Nuvalent to Present New Preclinical Data on HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, zidesamtinib, at AACR Annual Meeting 2024 · Persbericht

27 februari 2024 · Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones and Reports Fourth Quarter and Full Year 2023 Financial Results · Persbericht

27 februari 2024 · Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-520 · Persbericht

12 februari 2024 · Nuvalent Initiates the Phase 2 Portion of ALKOVE-1 Clinical Trial for Patients with ALK-Positive NSCLC and other Solid Tumors · Persbericht

1 februari 2024 · Nuvalent to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference · Persbericht

8 januari 2024 · Nuvalent Announces "OnTarget 2026" Operating Plan and Key Anticipated Milestones · Persbericht

21 december 2023 · Nuvalent to Present at the 42nd Annual J.P. Morgan Healthcare Conference · Persbericht

1 november 2023 · Nuvalent to Participate in the BMO Virtual BioPharma Spotlight Series: Oncology Day · Persbericht

17 oktober 2023 · Nuvalent Announces Pricing of Public Offering of Common Stock · Persbericht

16 oktober 2023 · Nuvalent Announces Public Offering of Common Stock · Persbericht

13 oktober 2023 · Nuvalent Reports Preliminary Phase 1 Clinical Data from ALKOVE-1 Trial that Support Best-In-Class Potential of NVL-655 for Patients with ALK-Positive NSCLC · Persbericht

4 oktober 2023 · Preliminary Phase 1 Dose-Escalation Data from ALKOVE-1 Trial of NVL-655 Demonstrated Activity in Heavily Pre-Treated Patients with ALK-Positive NSCLC and an ALK-Selective, TRK-Sparing Safety Profile · Persbericht

18 september 2023 · Nuvalent to Present Preliminary Data from ALKOVE-1 Phase 1/2 Clinical Trial of NVL-655 at 35th AACR-NCI-EORTC Symposium · Persbericht

5 september 2023 · Nuvalent Initiates the Phase 2 Portion of ARROS-1 Clinical Trial for Patients with ROS1-Positive NSCLC and other Solid Tumors · Persbericht

31 augustus 2023 · Nuvalent to Participate in Upcoming September Investor Conferences · Persbericht

10 augustus 2023 · Nuvalent Highlights Pipeline Progress and Reports Second Quarter 2023 Financial Results · Persbericht

1 augustus 2023 · Nuvalent to Participate in Upcoming August Investor Conferences · Persbericht

Mijn selecties